NdeaWinter 2026Active☆Watch⊞Compare

Ndea is one of 310 Pharma companies tracked from Remote, on record since 2026. By capital raised it ranks in the long tail (ahead of 16% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Building AGI that can innovate.

Ndea is building frontier AI systems that blend intuitive pattern recognition and formal reasoning into a unified architecture. # AI for Scientific Advancement Unlike all life before us, humanity's ascent is a story of ingenuity, not just biological evolution. Our progress has been driven by the curiosity to acquire knowledge, the ability to pass it on, and an intrinsic drive to innovate. We build technology which gives us leverage beyond our biology. We stand at the top of a knowledge and technology colossus that we collectively created over the past ten thousand generations. Scientific progress has helped us overcome burdens that long defined human life — famines, plagues, and widespread illiteracy. Science will continue to redefine the boundaries of the human condition. Today, the acceleration of scientific progress hinges on one factor: AI capable of independent invention and discovery. This capacity is the gateway to advancements beyond our wildest imagination. # A New Research Lab We're starting Ndea — an AI research and science lab. The name - like 'idea' with an 'n' - is inspired by the Greek concepts ennoia (intuitive understanding) and dianoia (logical reasoning), capturing our first goal to merge deep learning with program synthesis. Ndea is entirely focused on developing and operationalizing AGI to realize unprecedented scientific progress in our lifetime for the benefit of all current and future generations. Building AGI alone is a monumental undertaking, but our mission is even bigger. We're creating a factory for rapid scientific advancement — a factory capable of inventing and commercializing N ideas. From our vantage point today, we see many 'known' frontiers like self-driving vehicles, drug discovery, sustainable energy, robotics, and space exploration. While AGI will benefit all of these, the most exciting adventure lies in the 'unknown'. AGI promises discoveries and progress we cannot imagine today.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 16% of sector peers (real $). Modeled value above 16% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Ndea is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Ndea sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Ndea, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.